Home > Histone Methyltransferase & > Entacapone

Entacapone

恩他卡朋,OR-611,OR 611,OR611

Entacapone是特异的外周活性的邻苯二酚-O-甲基转移酶（COMT）抑制剂，IC50为151 nM。

目录号
EY0726
EY0726
EY0726
纯度
99.53%
99.53%
99.53%
规格
5 mg
10 mg
50 mg
原价
320
520
1650
售价
320
520
1650
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Entacapone inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] De Santi C, et al. Eur J Clin Pharmacol, 1998, 54(3), 215-219.
    [2] Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993)

    分子式
    C14H15N3O5    		 分子量
    305.29    		 CAS号
    130929-57-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    65 mg/mL    		 Water
    Insoluble     		Ethanol
    5 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02349243 Obesity Drug: Entacapone|Drug: Placebo Kaichun Wu|National Institute of Biological Sciences, Beijing|Fourth Military Medical University Phase 1|Phase 2 2015-01-01 2015-01-30
    NCT00192855 Schizophrenia Drug: Entacapone Rambam Health Care Campus 2003-06-01 2010-08-24
    NCT00547911 Parkinson Disease|Multiple System Atrophy|Autonomic Nervous System Diseases Drug: Droxidopa|Drug: Carbidopa|Drug: Entacapone National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Phase 1|Phase 2 2007-10-01 2014-06-17
    NCT00391898 Parkinson's Disease Drug: Levodopa/carbidopa/entacapone|Drug: Levodopa/carbidopa Novartis Phase 4 2006-10-01 2011-02-16
    NCT02058966 Methamphetamine Dependence Drug: Entacapone|Drug: Methamphetamine|Drug: Placebo Oregon Health and Science University|Portland VA Medical Center Early Phase 1 2014-06-01 2016-12-30
    NCT00237263 Parkinson's Disease Drug: Entacapone Novartis Phase 2 2003-02-01 2017-02-21
    NCT00219284 Parkinson's Disease With End of Dose "Wearing Off" Drug: Carbidopa/levodopa/entacapone Novartis Pharmaceuticals|Novartis Phase 4 2005-01-01 2011-02-16
    NCT00099268 Parkinson's Disease Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis Phase 3 2004-09-01 2012-04-19
    NCT00642356 Parkinson's Disease Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa Novartis Phase 4 2008-03-01 2011-02-16
    NCT00415740 Healthy Drug: ELC200 (carbidopa+levodopa+entacapone) Novartis Phase 1 2006-05-01 2007-06-21
    NCT00415831 Healthy Drug: ELC200 (carbidopa+levodopa+entacapone) Novartis Phase 1 2006-06-01 2007-06-21
    NCT00415922 Healthy Drug: ELC200 (carbidopa+levodopa+entacapone) Novartis Phase 1 2006-07-01 2007-06-21
    NCT00415844 Healthy Drug: ELC200 (carbidopa+levodopa+entacapone) Novartis Phase 1 2006-06-01 2007-06-21
    NCT01130493 Parkinson's Disease Drug: IPX066|Drug: Carbidopa/Levodopa/Entacapone IMPAX Laboratories, Inc. Phase 3 2010-05-01 2013-09-27
    NCT01437293 Cocaine Abuse Drug: L-dopa / carbidopa / entacapone (LCE) New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)|Columbia University Phase 1 2010-08-01 2012-10-25
    NCT00143026 Parkinson's Disease Drug: carbidopa, levodopa, entacapone Novartis Phase 4 2005-07-01 2011-11-22
    NCT00134966 Parkinson's Disease Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) Novartis Phase 3 2005-08-01 2008-03-28
    NCT00601978 Parkinson's Disease Drug: carbidopa/levodopa|Drug: Carbidopa/Levodopa/Entacapone Novartis Pharmaceuticals|Novartis Phase 4 2008-08-01 2012-04-27
    NCT01296464 Parkinson's Disease Drug: Carbidopa Orion Corporation, Orion Pharma Phase 2 2011-02-01 2011-09-09
    NCT02448914 Parkinson's Disease Drug: TRIGEL|Drug: Duodopa LobSor Pharmaceuticals AB|TFS Trial Form Support Phase 1 2015-05-01 2016-04-19

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：